Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Venture Capital

Pharmastandard International Leads $20M Series C In Avelas Biosciences

by vcnewsdaily.com posted 1year ago 2794 views
Avelas Biosciences, a clinical stage oncology-focused company dedicated to improving cancer patient care from diagnosis through treatment, today announced it has completed a Series C financing which raised $20 million.